摘要
目的分析小细胞肺癌应用安罗替尼联合伊立替康二线治疗方案的临床效果,并观察用药的安全性。方法选择大庆市人民医院2019年1月—2021年1月收治的54例小细胞肺癌患者为研究对象,基于单盲分组方式对患者进行划分组别,名称为参照组(27例)与观察组(27例)。参照组应用伊立替康为患者治疗,观察组应用安罗替尼联合伊立替康对患者实施治疗。对两组患者疾病治疗效果、血清指标及不良反应情况进行对比。结果观察组患者临床治疗有效控制率为92.59%,客观缓解率为62.96%,均优于参照组,差异有统计学意义(χ^(2)=5.594、6.033,P<0.05);观察组患者血管内皮生长因子为(391.92±103.54)μg/L、多效蛋白为(310.33±34.65)ng/L,优于对照组,差异有统计学意义(t=3.131、6.447,P<0.001)。结论小细胞肺癌患者应用安罗替尼联合伊立替康二线治疗方案,可以有效提升临床治疗的疾病缓解率,改善患者临床症状,降低患者不良反应,对患者预后具有积极意义。
Objective To analyze the clinical effect of anlotinib combined with irinotecan in the second-line treat⁃ment of small cell lung cancer,and to observe the safety of the drug.Methods A total of 54 patients with small cell lung cancer who were treated in Daqing People's Hospital from January 2019 to January 2021 were selected as the research objects,and the patients were divided into groups based on single-blind grouping,named as the reference group(27 cases)and the observation group(27 cases),the reference group was treated with irinotecan,and the obser⁃vation group was treated with anlotinib combined with irinotecan.The treatment effect,serum indexes and adverse re⁃actions of the two groups were compared.Results The effective control rate of clinical treatment in the observation group was 92.59%,and the objective remission rate was 62.96%,which were both better than those in the reference group,and the difference was statistically significant(χ^(2)=5.594,6.033,P<0.05);the vascular endothelial growth fac⁃tor of the observation group was(391.92±103.54)μg/L,pleiotropin was(310.33±34.65)ng/L,better than the refer⁃ence group,the difference was statistically significant(t=3.131,6.447,P<0.001).Conclusion The application of anlo⁃tinib combined with irinotecan second-line therapy in patients with small cell lung cancer can effectively increase the disease remission rate,improve the clinical symptoms,and reduce the adverse reactions of patients,which has positive significance for the prognosis of patients.
作者
李晓通
杜红梅
LI Xiaotong;DU Hongmei(The First Department of Oncology,Daqing People's Hospital,Daqing,Heilongjiang Province,163000 China;Health and Nursing,Qiqihar Engineering College,Qiqihar,Heilongjiang Province,161000 China)
出处
《系统医学》
2022年第11期165-168,共4页
Systems Medicine
